Jasper debuts with $35M series A, licenses antibody from Amgen to prep patients for transplants

With an antibody in-licensed from Amgen and a $35 million series A led by Abingworth and Qiming Venture Partners, Jasper is aiming to make stem cell transplants safer for patients.

Surveyor Capital and Alexandria Venture Investments also participated in the financing. Separately, the California

Read the full 436 word article

User Sign In